Format

Send to

Choose Destination
Expert Rev Vaccines. 2011 Jun;10(6):811-23. doi: 10.1586/erv.11.68.

Neuroendocrine cancer vaccines in clinical trials.

Author information

1
Centre for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8N 3Z5, Canada. bridleb@mcmaster.ca

Abstract

This article focuses on neuroendocrine cancer vaccines that have been evaluated in human clinical trials within the last 5 years. The definition of what constitutes a neuroendocrine tumor requires clarification. Strategies and barriers common to cancer vaccines are highlighted. In general, neuroendocrine cancer is rare; however, special attention will be paid to neuroblastoma and small-cell-lung cancer owing to their relatively higher prevalence. A variety of other neuroendocrine tumor vaccine trials will also be addressed. The common problem of generating only sporadic tumor-specific immune responses that are of low-magnitude will be discussed in detail, with recommendations for future directions.

PMID:
21692702
DOI:
10.1586/erv.11.68
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center